⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRNX News
Crinetics Pharmaceuticals, Inc.
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
prnewswire.com
CRNX
NVS
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
globenewswire.com
CRNX
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CRNX
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
CRNX
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CRNX
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
globenewswire.com
CRNX
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
globenewswire.com
CRNX